NMDAR antagonists for the treatment of diabetes mellitus-Current status and future directions

Area of Science:

• Endocrinology
• Neuroscience
• Pharmacology

Background:

• Diabetes mellitus involves high blood glucose and loss of insulin-producing beta-cells.
• Current diabetes medications offer limited beta-cell preservation.
• Pancreatic N-methyl-D-aspartate receptors (NMDARs) role in beta-cell function is under investigation.

Purpose of the Study:

• To review evidence on pancreatic NMDARs in beta-cell physiology.
• To summarize the effects of NMDAR antagonists on insulin secretion, glucose tolerance, and beta-cell survival.
• To explore NMDARs' role in diabetic complications and the therapeutic potential of antagonists.

Main Methods:

• Literature review of existing studies on NMDARs in pancreatic beta-cells.
• Analysis of research on morphinan-based NMDAR antagonists.
• Examination of molecular pathways involved in NMDAR-mediated cell survival.
• Review of studies on NMDARs in diabetic nephropathy, retinopathy, and neuropathy.

Main Results:

• NMDAR antagonists show beneficial effects on insulin secretion, glucose tolerance, and beta-cell survival.
• NMDAR-mediated pathways may be crucial for preserving beta-cell function and mass.
• NMDARs are implicated in the development of long-term diabetic complications.
• NMDAR antagonists demonstrate potential therapeutic benefits for diabetic nephropathy, retinopathy, and neuropathy.

Conclusions:

• Pancreatic NMDARs play a significant role in beta-cell physiology and survival.
• NMDAR antagonists represent a promising therapeutic strategy for type 2 diabetes and its complications.
• Targeting NMDARs could offer a novel approach to preserve beta-cell mass and function, and mitigate long-term diabetic damage.